Physician profile
Daniel P Leonard
NPI 1366671489
$5,114.66
in general payments reported to CMS, 2019-2025
11 companies · $4,620 in 2025
The $4,620 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.00 · 2022: $21.96 · 2024: $437 · 2025: $4,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,626 · Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,625.86 |
| Food and Beverage | $930.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,125.86 | 2025 | |
| Glaxosmithkline, LLC. | $384.90 | 2024-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $118.72 | 2024-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $111.06 | 2022-2025 | |
| Philips North America LLC | $94.70 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Patient Interface Software |
| Astrazeneca Pharmaceuticals LP | $69.85 | 2019-2025 | Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.82 | 2024-2025 | Ofev |
| Amgen INC. | $63.03 | 2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $45.11 | 2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $36.61 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.